miR-486-5p modulates survival and imatinib sensitivity of BCR-ABL–transformed cells. (A) Apoptosis of BCR-ABL–expressing TF-1 cells transduced with miRZip-anti486-5p or scramble control vectors and treated with IM (2.5 μM) for 48 hours. (B) Apoptosis of CB CD34⁺ cells transduced with BCR-ABL and then miRZip-anti486-5p or scramble control vectors and treated with IM (2.5 µM) for 48 hours. (C) Apoptosis of CB CD34⁺ cells transduced with MIG-R1 control vector followed by miRZip-anti486 or scramble control vectors and treated with IM (2.5 µM) for 48 hours. (D-F) CML CD34⁺ cells were transduced with miRZip-anti-486-5p and scramble vector and selected with puromycin in HGF medium for 3 days. FoxO1(D), PTEN (E), and p-AKT (F) expression was detected by western blotting. (G) CML CD34⁺ cells were transduced with scramble control and miRZip-Ef1-anti-486-5p vector, respectively. The transduced cells were stained with Dye670 and cultured in HGF for 3 days. The proliferation index was determined. Inhibition of proliferation as compared with scramble sequences is shown (n = 3). (H) The fold increase of cell number of scramble and miRZip-EF1-anti486-5p–transduced CML CD34⁺ cells in the SFEM with HGF. (I) Apoptosis of CML CD34⁺ cells transduced with miRZip-anti486 or scramble control vectors and treated with IM (2.5 µM) for 48 hours. Cumulative results represent the mean ± SEM. *P < .05, **P < .01, ***P < .001.